---
title: Antidepressant Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antidepressants, SSRIs, SNRIs, TCAs, MAOIs, depression, serotonin-syndrome, anxiety]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antidepressant Drugs

## Introduction

Antidepressants are medications primarily used to treat major depressive disorder (MDD), but have broad applications including anxiety disorders, chronic pain, and other psychiatric conditions. Understanding the different classes, mechanisms, and side effect profiles is essential for safe and effective prescribing.

## Classification

### Major Classes

1. **Selective Serotonin Reuptake Inhibitors (SSRIs)**
   - First-line for most depressive/anxiety disorders

2. **Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**
   - Dual mechanism

3. **Tricyclic Antidepressants (TCAs)**
   - Older, effective but more toxic

4. **Monoamine Oxidase Inhibitors (MAOIs)**
   - Reserved for treatment-resistant cases

5. **Atypical Antidepressants**
   - Bupropion, mirtazapine, trazodone, vilazodone, vortioxetine

---

## Monoamine Theory of Depression

**Historical Hypothesis**:
- Depression results from deficiency of monoamine neurotransmitters
- Serotonin (5-HT), norepinephrine (NE), dopamine (DA)

**Supporting Evidence**:
- Reserpine (depletes monoamines) → depression
- Antidepressants ↑synaptic monoamines

**Limitations**:
- Monoamine levels ↑immediately with drugs, but clinical effect takes 2-4 weeks
- Not all patients respond to monoamine manipulation

**Modern Understanding**:
- Chronic ↑monoamines → downregulation of presynaptic autoreceptors
- Neuroplasticity changes (BDNF, neurogenesis)
- Receptor sensitivity changes
- Multiple mechanisms likely involved

---

## Selective Serotonin Reuptake Inhibitors (SSRIs)

### Mechanism of Action

**Primary**: Block serotonin reuptake transporter (SERT) → ↑synaptic 5-HT

**Time Course**:
1. **Immediate** (hours): ↑5-HT in synapse
2. **Days-weeks**: Desensitization of 5-HT1A autoreceptors
3. **Weeks**: Downregulation of 5-HT2 receptors
4. **Clinical effect**: 2-4 weeks (sometimes up to 8 weeks)

**Selectivity**: Minimal effects on NE, DA, histamine, muscarinic, α-adrenergic receptors
- Advantage: Fewer side effects than TCAs
- Better safety profile in overdose

### Individual SSRIs

#### Fluoxetine (Prozac)

**Pharmacokinetics**:
- Oral
- **Long half-life**: 1-4 days (active metabolite norfluoxetine: 7-15 days)
- **No withdrawal syndrome** (self-tapering)
- Hepatic metabolism (CYP2D6 inhibitor, CYP2C19)

**Clinical Uses**:
1. Major depressive disorder (MDD)
2. Obsessive-compulsive disorder (OCD)
3. Bulimia nervosa (FDA-approved)
4. Panic disorder
5. Premenstrual dysphoric disorder (PMDD) - Sarafem

**Advantages**:
- Once-weekly formulation available (Prozac Weekly)
- Activating (may help fatigue)
- Long half-life (no withdrawal)

**Disadvantages**:
- Activating → anxiety, insomnia initially
- Long half-life → slow to clear if side effects

**Dosing**: 20-80 mg/day (usual: 20 mg)

#### Sertraline (Zoloft)

**Pharmacokinetics**:
- Oral
- Half-life: 26 hours
- Moderate CYP2D6 inhibition (less than fluoxetine)

**Clinical Uses**:
1. MDD
2. OCD
3. Panic disorder
4. PTSD (FDA-approved)
5. Social anxiety disorder
6. PMDD

**Advantages**:
- Well-tolerated
- Mild dopamine reuptake inhibition (may help motivation)
- Safe in cardiac disease

**Disadvantages**:
- GI side effects common
- Diarrhea more frequent

**Dosing**: 50-200 mg/day (usual: 50-100 mg)

#### Paroxetine (Paxil)

**Pharmacokinetics**:
- Oral (IR, CR)
- Half-life: 21 hours
- **Strong CYP2D6 inhibitor**
- **Most anticholinergic** SSRI

**Clinical Uses**:
1. MDD
2. Panic disorder
3. Social anxiety disorder
4. Generalized anxiety disorder (GAD)
5. OCD
6. PTSD

**Advantages**:
- Sedating (helpful for anxiety, insomnia)
- Anxiolytic properties

**Disadvantages**:
- **Worst withdrawal syndrome** (short half-life, anticholinergic)
- Weight gain (most of SSRIs)
- Sedation
- Anticholinergic effects
- Most drug interactions
- **Highest risk of birth defects** (cardiac - avoid in pregnancy)

**Dosing**: 20-60 mg/day (usual: 20 mg)

#### Citalopram (Celexa)

**Pharmacokinetics**:
- Oral
- Half-life: 35 hours
- Minimal drug interactions (better than others)

**Clinical Uses**:
1. MDD (FDA-approved)
2. Anxiety disorders (off-label)

**Advantages**:
- Well-tolerated
- Minimal drug interactions
- Fewer discontinuation symptoms

**Disadvantages**:
- **QTc prolongation** (dose-dependent)
  - **Max dose: 40 mg/day** (FDA recommendation)
  - Max 20 mg/day if >60 years, poor CYP2C19 metabolizers

**Dosing**: 20-40 mg/day (max 40 mg due to QTc)

#### Escitalopram (Lexapro)

**Pharmacokinetics**:
- S-enantiomer of citalopram (active enantiomer)
- Oral
- Half-life: 27-32 hours
- Minimal drug interactions

**Clinical Uses**:
1. MDD
2. Generalized anxiety disorder (GAD)

**Advantages**:
- **Most selective** SSRI
- Excellent tolerability
- Efficacy at lower doses than citalopram
- Minimal drug interactions
- Fast onset (may see improvement in 1-2 weeks)

**Disadvantages**:
- QTc prolongation (less than citalopram)
- More expensive (though generic available)

**Dosing**: 10-20 mg/day (usual: 10 mg)

**Clinical Pearl**: Often considered best-tolerated SSRI

#### Fluvoxamine (Luvox)

**Pharmacokinetics**:
- Oral (IR, ER)
- Half-life: 15 hours
- **Strong CYP1A2 and CYP2C19 inhibitor**

**Clinical Uses**:
1. **OCD** (FDA-approved)
2. Social anxiety disorder
3. MDD (off-label in US)

**Advantages**:
- Effective for OCD

**Disadvantages**:
- **Most drug interactions** (strong CYP inhibitor)
- BID dosing (IR)
- GI side effects
- Sedation

**Dosing**: 100-300 mg/day

**Note**: Less commonly used due to drug interactions

### SSRI Adverse Effects

**Common (All SSRIs)**:

1. **GI Effects** (most common initially):
   - Nausea, diarrhea, dyspepsia
   - Mechanism: 5-HT3 activation in gut
   - Usually improve after 1-2 weeks
   - Take with food

2. **Sexual Dysfunction** (40-60%):
   - ↓Libido, delayed orgasm, erectile dysfunction
   - Mechanism: 5-HT2 activation
   - Often persistent (doesn't resolve)
   - Management: Dose reduction, switch to bupropion/mirtazapine, add bupropion, sildenafil

3. **CNS Effects**:
   - Headache, dizziness
   - Insomnia or somnolence
   - Activation/anxiety (initially)
   - Tremor

4. **Weight Changes**:
   - Acute: Weight loss (appetite suppression)
   - Chronic: Weight gain (especially paroxetine)

5. **Hyponatremia (SIADH)**:
   - More common in elderly
   - Monitor sodium, especially first months
   - Mechanism: ↑ADH secretion

6. **Bleeding**:
   - Serotonin in platelets (no synthesis)
   - SSRI ↓platelet serotonin → ↑bleeding risk
   - Especially with NSAIDs, warfarin, antiplatelet agents

**Less Common**:

7. **Serotonin Syndrome** (see below):
   - Excess serotonergic activity
   - Risk with drug combinations

8. **Discontinuation Syndrome**:
   - Paroxetine > sertraline, citalopram, escitalopram > fluoxetine (rare)
   - See below

9. **QTc Prolongation**:
   - Citalopram > escitalopram >> others

10. **Activation/Akathisia**:
    - Restlessness, agitation
    - More with fluoxetine

**Black Box Warning**:
- **Increased suicidality in children, adolescents, young adults (<25 years)**
- Monitor closely, especially first 1-2 months
- Risk highest in first month

### SSRI Drug Interactions

**CYP Enzyme Inhibition**:
- **Fluoxetine**: Strong 2D6 inhibitor
- **Paroxetine**: Strong 2D6 inhibitor
- **Fluvoxamine**: Strong 1A2, 2C19 inhibitor
- **Sertraline**: Moderate 2D6 inhibitor
- **Citalopram, escitalopram**: Minimal

**Consequence**: ↑Levels of drugs metabolized by these enzymes
- TCAs, antipsychotics, β-blockers (2D6)
- Theophylline, clozapine (1A2)
- Warfarin (2C19)

**Serotonin Syndrome Risk** (see below):
- MAOIs, tramadol, triptans, linezolid, St. John's Wort

**Bleeding Risk**:
- NSAIDs, aspirin, warfarin, antiplatelet agents

---

## Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

### Mechanism of Action

**Dual reuptake inhibition**: SERT and NET → ↑5-HT and ↑NE

**Advantages**:
- Dual mechanism may help patients who don't respond to SSRIs
- NE activity → may help pain, fatigue, concentration

### Individual SNRIs

#### Venlafaxine (Effexor)

**Mechanism**:
- **Dose-dependent selectivity**:
  - Low doses (<150 mg): Primarily SERT (like SSRI)
  - High doses (>150 mg): SERT + NET (SNRI)
  - Very high doses: SERT + NET + weak DAT

**Pharmacokinetics**:
- Oral (IR, XR)
- Half-life: 5 hours (active metabolite desvenlafaxine: 11 hours)
- Hepatic metabolism (CYP2D6)

**Clinical Uses**:
1. MDD
2. Generalized anxiety disorder (GAD)
3. Social anxiety disorder
4. Panic disorder
5. Neuropathic pain (off-label)
6. Hot flashes (off-label)

**Advantages**:
- Effective for depression and anxiety
- May help pain
- Dose can be titrated to optimize NE activity

**Adverse Effects**:
- Similar to SSRIs plus:
- **Hypertension** (NE, dose-dependent): Monitor BP, especially >150 mg/day
- **Sweating** (NE)
- **Discontinuation syndrome** (common - short half-life)

**Dosing**:
- Start: 37.5-75 mg/day
- Therapeutic: 150-225 mg/day
- Max: 375 mg/day

#### Desvenlafaxine (Pristiq)

**Relationship**: Active metabolite of venlafaxine

**Pharmacokinetics**:
- Oral (ER)
- Half-life: 11 hours
- **Minimal hepatic metabolism** (renal excretion)
- Fewer drug interactions

**Advantages**:
- Predictable dosing (no CYP2D6 variability)
- Fixed dose (50 mg/day)

**Dosing**: 50-100 mg/day (50 mg usually sufficient)

#### Duloxetine (Cymbalta)

**Mechanism**: More balanced SERT/NET inhibition than venlafaxine

**Pharmacokinetics**:
- Oral (delayed-release capsule)
- Half-life: 12 hours
- Hepatic metabolism (CYP2D6, CYP1A2)

**Clinical Uses**:
1. MDD
2. Generalized anxiety disorder (GAD)
3. **Diabetic neuropathic pain** (FDA-approved)
4. **Fibromyalgia** (FDA-approved)
5. **Chronic musculoskeletal pain** (FDA-approved)
6. Stress urinary incontinence (off-label)

**Advantages**:
- **Excellent for pain** (neuropathic, fibromyalgia, chronic)
- Dual indication (depression + pain)

**Adverse Effects**:
- Similar to venlafaxine
- **Hepatotoxicity** (rare but serious)
  - Contraindicated in hepatic impairment
  - Monitor LFTs
- Nausea (common initially)

**Dosing**: 30-60 mg/day (pain: start 30 mg, depression: start 40-60 mg)

**Contraindications**:
- Hepatic impairment
- Severe renal impairment (CrCl <30)

#### Levomilnacipran (Fetzima)

**Mechanism**: More selective NET > SERT (opposite of other SNRIs)

**Clinical Uses**:
1. MDD

**Advantages**:
- Preferential NE activity (may help motivation, energy)

**Dosing**: 40-120 mg/day

#### Milnacipran (Savella)

**Indication**: **Fibromyalgia only** (not approved for depression in US)

**Mechanism**: Balanced SERT/NET

**Dosing**: 50 mg BID (titrate to 100 mg BID)

---

## Tricyclic Antidepressants (TCAs)

### Mechanism of Action

**Primary**: Block NET and SERT → ↑NE and 5-HT

**Additional Receptor Blockade** (responsible for side effects):
- **M1 (muscarinic)**: Anticholinergic effects
- **H1 (histamine)**: Sedation, weight gain
- **α1 (adrenergic)**: Orthostatic hypotension
- **Na+ channels**: Cardiac toxicity (QRS widening, arrhythmias)

**Classification**:

**Tertiary Amines** (more serotonergic, more side effects):
- Amitriptyline
- Imipramine
- Clomipramine
- Doxepin
- Trimipramine

**Secondary Amines** (more noradrenergic, fewer side effects):
- Nortriptyline
- Desipramine
- Protriptyline

### Pharmacokinetics

- Oral
- Extensive first-pass metabolism
- Long half-lives (12-24+ hours)
- Hepatic metabolism
- **Therapeutic drug monitoring** available (especially nortriptyline)

### Individual TCAs

#### Amitriptyline

**Profile**: Tertiary amine - most anticholinergic, most sedating

**Clinical Uses**:
1. MDD (second-line)
2. **Neuropathic pain** (common off-label use)
3. **Migraine prophylaxis** (common)
4. Insomnia (low dose, off-label)
5. Fibromyalgia

**Dosing**:
- Depression: 150-300 mg/day
- Pain/migraine: 10-75 mg qhs (lower doses)

**Advantages**: Effective for pain, migraine prophylaxis

**Disadvantages**: Most side effects of TCAs

#### Nortriptyline

**Profile**: Secondary amine - less anticholinergic, less sedating than amitriptyline

**Advantages**:
- **Best-tolerated TCA**
- **Less orthostatic hypotension** than others
- **Therapeutic window** (50-150 ng/mL) - can monitor levels
- Good for elderly

**Clinical Uses**: Similar to amitriptyline but better tolerated

**Dosing**: 75-150 mg/day

#### Imipramine

**Profile**: Tertiary amine

**Historical**: First TCA discovered (1950s)

**Clinical Uses**:
1. MDD
2. **Enuresis** (bedwetting in children)
3. Panic disorder

**Dosing**: 150-300 mg/day

#### Clomipramine

**Profile**: Tertiary amine, **most serotonergic TCA**

**Clinical Uses**:
1. **OCD** (FDA-approved, most effective TCA for OCD)
2. MDD

**Dosing**: 150-250 mg/day

**Advantages**: Highly effective for OCD

**Disadvantages**: High side effect burden (anticholinergic, sedation)

#### Desipramine

**Profile**: Secondary amine, **most noradrenergic TCA**

**Advantages**:
- Least anticholinergic
- Least sedating
- May help ADHD (off-label)

**Clinical Uses**: MDD, neuropathic pain

**Dosing**: 150-300 mg/day

#### Doxepin

**Clinical Uses**:
1. MDD
2. **Insomnia** (low-dose formulation: Silenor 3-6 mg)
3. Anxiety

**Low-dose Doxepin** (3-6 mg):
- Pure H1 antagonist (no other effects at low dose)
- FDA-approved for insomnia

**Dosing**:
- Depression: 150-300 mg/day
- Insomnia: 3-6 mg qhs

### TCA Adverse Effects

**Anticholinergic** (M1 blockade):
- Dry mouth, blurred vision (cycloplegia)
- Constipation, urinary retention
- Confusion, memory impairment (especially elderly)
- Hyperthermia (impaired sweating)

**Antihistaminic** (H1 blockade):
- Sedation
- Weight gain

**Anti-α1-adrenergic**:
- **Orthostatic hypotension** (most dangerous in elderly)
- Dizziness, falls
- Reflex tachycardia

**Cardiac**:
- **QRS prolongation** (Na+ channel blockade)
- PR prolongation (AV block)
- QT prolongation
- Arrhythmias (ventricular)
- **Contraindicated post-MI**
- **Lethal in overdose** (cardiac toxicity)

**Other**:
- Sexual dysfunction
- Weight gain (H1, 5-HT2C)
- Seizures (lower threshold)
- Tremor

**Black Box Warning**: Suicidality (like all antidepressants)

### TCA Contraindications

- **Recent MI** (within 6 months)
- **Cardiac conduction abnormalities** (bundle branch block, QT prolongation)
- **Acute angle-closure glaucoma**
- **Urinary retention**, **BPH**
- Within 14 days of MAOI

### TCA Overdose

**Clinical Features**:
- **Anticholinergic toxidrome**: Dry mouth, mydriasis, hyperthermia, delirium
- **Cardiac**: QRS widening (>100 ms), arrhythmias, hypotension
- **CNS**: Seizures, coma
- **"Three Cs"**: Coma, Convulsions, Cardiotoxicity

**Treatment**:
1. **ABC stabilization**
2. **Sodium bicarbonate** (for QRS >100 ms or arrhythmias)
   - Overcomes Na+ channel blockade
   - Target pH 7.50-7.55
3. **Activated charcoal** (if within 1 hour)
4. **Benzodiazepines** for seizures
5. **Avoid Class IA and IC antiarrhythmics** (worsen Na+ blockade)

**Lethality**: TCAs highly lethal in overdose (major concern in suicidal patients)

### TCA Drug Interactions

- **MAOIs**: Hypertensive crisis, serotonin syndrome
- **CYP2D6 inhibitors** (fluoxetine, paroxetine): ↑TCA levels
- **Anticholinergics**: Additive effects
- **Sympathomimetics**: ↑pressor response
- **CNS depressants**: Additive sedation

---

## Monoamine Oxidase Inhibitors (MAOIs)

### Mechanism of Action

**MAO Enzyme**:
- **MAO-A**: Metabolizes NE, 5-HT, tyramine
- **MAO-B**: Metabolizes dopamine

**Traditional MAOIs**: Irreversible, non-selective inhibition (MAO-A and MAO-B)
- ↑NE, 5-HT, DA (antidepressant effect)
- ↑Tyramine (dietary concern)

### Individual MAOIs

#### Phenelzine

**Profile**: Irreversible, non-selective MAOI

**Clinical Uses**:
1. **Atypical depression** (with hypersomnia, hyperphagia, rejection sensitivity)
2. **Treatment-resistant depression**
3. Panic disorder
4. Social anxiety disorder

**Dosing**: 45-90 mg/day (divided doses)

#### Tranylcypromine

**Profile**: Irreversible, non-selective MAOI
- **Most stimulating** MAOI (amphetamine-like structure)

**Clinical Uses**: Similar to phenelzine

**Dosing**: 30-60 mg/day

#### Isocarboxazid

**Profile**: Irreversible, non-selective MAOI

**Dosing**: 20-60 mg/day

#### Selegiline

**Profile**:
- **MAO-B selective** at low doses (<10 mg)
- Non-selective at higher doses

**Formulations**:
- **Transdermal patch (Emsam)**: Lower dietary restrictions at 6 mg/24h
- Oral: For Parkinson's disease (MAO-B selective)

**Clinical Uses**:
1. MDD (transdermal)
2. Parkinson's disease (oral, low dose)

**Advantages**:
- **Transdermal 6 mg/24h**: No dietary restrictions (bypasses gut MAO-A)
- Better tolerability

**Dosing**:
- Transdermal: 6-12 mg/24h
- Dietary restrictions required if >6 mg/24h

#### Moclobemide

**Profile**: **Reversible MAO-A inhibitor (RIMA)**

**Status**: **Not available in US** (available in Canada, Europe)

**Advantages**:
- Reversible → safer
- Fewer dietary restrictions (tyramine can displace)
- Shorter washout period

**Dosing**: 300-600 mg/day

### MAOI Adverse Effects

**Common**:
- Orthostatic hypotension (most common)
- Insomnia, agitation
- Sexual dysfunction
- Weight gain
- Peripheral edema

**Serious**:

1. **Hypertensive Crisis** (tyramine reaction):
   - See below

2. **Serotonin Syndrome**:
   - With other serotonergic drugs
   - See below

### Tyramine Reaction (Hypertensive Crisis)

**Mechanism**:
1. Tyramine (indirect sympathomimetic) in food/drinks
2. Normally metabolized by MAO-A in gut
3. MAOI → ↑tyramine absorption → systemic tyramine
4. Tyramine displaces NE from vesicles
5. Massive NE release → **hypertensive crisis**

**Clinical Features**:
- Severe headache (occipital, throbbing)
- Hypertension (SBP >180)
- Tachycardia or bradycardia
- Diaphoresis
- Nausea, vomiting
- Chest pain
- Risk: Intracranial hemorrhage, MI

**High Tyramine Foods (AVOID)**:
- **Aged cheeses** (cheddar, blue, parmesan)
- **Cured/smoked meats** (salami, pepperoni)
- **Fermented foods** (sauerkraut, kimchi, miso)
- **Tap beer, red wine**
- **Fava beans**
- **Soy sauce, yeast extracts**
- Overripe bananas, avocados

**Safe Foods**: Fresh meat, fresh dairy, fresh produce

**Treatment**:
1. **Phentolamine** (α-blocker): 5 mg IV
2. **Nifedipine** (CCB): 10 mg SL/PO
3. **Avoid β-blockers** (unopposed α)
4. Supportive care

### MAOI Dietary and Drug Restrictions

**Dietary**:
- Avoid high-tyramine foods (see above)
- Restrictions continue **2 weeks after stopping MAOI** (time for MAO regeneration)

**Drug Interactions**:

**Absolutely Contraindicated**:
1. **Other antidepressants** (SSRIs, SNRIs, TCAs):
   - **14-day washout before MAOI**
   - **14-day washout after MAOI** (before starting other)
   - Exception: **5 weeks after fluoxetine** (long half-life)

2. **Serotonergic drugs**:
   - Meperidine (Demerol) - serotonin syndrome
   - Tramadol, methadone
   - Dextromethorphan
   - St. John's Wort
   - Triptans (sumatriptan)
   - Linezolid (antibiotic with MAOI activity)

3. **Sympathomimetics**:
   - Pseudoephedrine, phenylephrine
   - Amphetamines
   - Cocaine

**Caution**:
- Opioids (meperidine contraindicated; use morphine with caution)
- General anesthesia

### MAOI Clinical Pearls

- **Reserve for treatment-resistant depression** or atypical depression
- **Patient must be reliable** (dietary/drug compliance)
- **Carry phentolamine or nifedipine** for hypertensive crisis
- **Medic-Alert bracelet** recommended
- **14-day washout** before/after (5 weeks after fluoxetine)

---

## Serotonin Syndrome

**Definition**: Life-threatening condition from excess serotonergic activity

**Causes**:
- **Drug combinations**: MAOI + SSRI, SSRI + tramadol, SSRI + linezolid, SSRI + triptan
- **Overdose**: SSRI, SNRI
- **Drug interactions**: Multiple serotonergic drugs

**Clinical Features** (Sternbach Criteria):

**Triad**:
1. **Mental status changes**: Agitation, confusion, delirium
2. **Autonomic hyperactivity**: Hyperthermia, diaphoresis, tachycardia, hypertension, mydriasis
3. **Neuromuscular abnormalities**:
   - **Clonus** (spontaneous or inducible)
   - **Hyperreflexia** (especially lower extremities)
   - Rigidity, tremor

**Severity Spectrum**:
- **Mild**: Tremor, hyperreflexia, diaphoresis, mydriasis
- **Moderate**: + Agitation, hyperthermia (<40°C), hyperactive bowel sounds, clonus
- **Severe**: + Severe hyperthermia (>40°C), rigidity, delirium, shock

**Diagnosis**: Clinical (no specific test)

**Differential Diagnosis**:
- **Neuroleptic malignant syndrome** (NMS):
  - Slower onset (days)
  - "Lead-pipe" rigidity (not clonus)
  - ↓Reflexes (not hyperreflexia)
  - History of antipsychotics
  - ↑CK (more marked)
- **Malignant hyperthermia**: Anesthesia exposure
- **Anticholinergic toxicity**: ↓Bowel sounds, dry skin

**Treatment**:

1. **Stop serotonergic agents**
2. **Supportive care**:
   - ABC stabilization
   - Cooling (hyperthermia)
   - IV fluids
   - Benzodiazepines (agitation, rigidity)

3. **Cyproheptadine** (5-HT2A antagonist):
   - 12 mg initial, then 2 mg q2h until improvement
   - Max 32 mg/day

4. **Severe cases**:
   - ICU admission
   - Intubation/sedation/paralysis if severe hyperthermia
   - Treat rhabdomyolysis, DIC

**Prognosis**: Good if recognized early and treated

**Prevention**:
- Avoid drug combinations
- Appropriate washout periods (MAOIs)
- Educate patients on risks

---

## Discontinuation Syndrome

**Definition**: Withdrawal symptoms when stopping antidepressants abruptly

**Risk Factors**:
- **Short half-life** drugs (paroxetine > venlafaxine, desvenlafaxine > sertraline > citalopram, escitalopram >> fluoxetine)
- Abrupt cessation (vs. taper)
- Higher doses
- Longer duration of treatment

**Clinical Features** (mnemonic: **FINISH**):
- **F**lu-like symptoms (fatigue, myalgia)
- **I**nsomnia, vivid dreams
- **N**ausea, diarrhea
- **I**mbalance (dizziness, vertigo)
- **S**ensory disturbances ("brain zaps" - electric shock sensations)
- **H**yperarousal (anxiety, agitation)

**Onset**: 1-7 days after stopping (or dose reduction)

**Duration**: Days to weeks (usually self-limited)

**Treatment**:
1. **Restart antidepressant** → symptoms resolve in hours
2. **Taper slowly** (over weeks to months)
3. Symptomatic treatment

**Prevention**: **Gradual taper** (reduce by 25-50% every 1-2 weeks)

**Note**: **Fluoxetine rarely causes discontinuation syndrome** (long half-life - self-tapering)

---

## Atypical Antidepressants

### Bupropion (Wellbutrin, Zyban)

**Mechanism**: NE and DA reuptake inhibitor (NDRI) - **no serotonergic activity**

**Pharmacokinetics**:
- Oral (IR, SR, XL)
- Hepatic metabolism (CYP2B6) → active metabolites
- Half-life: 21 hours (XL)

**Clinical Uses**:
1. **MDD** (first-line alternative to SSRIs)
2. **Seasonal affective disorder** (SAD) - XL formulation
3. **Smoking cessation** (Zyban)
4. **ADHD** (off-label)
5. **Adjunct to SSRI** (for sexual dysfunction, weight gain)

**Advantages**:
- **No sexual dysfunction** (unique among antidepressants)
- **No weight gain** (may cause weight loss)
- **Activating** (may help fatigue, motivation)
- Helps smoking cessation

**Adverse Effects**:
- **Seizures** (dose-dependent):
  - Risk: 0.1% (<300 mg/day), 0.4% (300-450 mg/day)
  - **Contraindicated**: Seizure disorder, eating disorders (↑seizure risk), abrupt alcohol/benzodiazepine withdrawal
  - **Max dose**: 450 mg/day (XL), 400 mg/day (SR), 300 mg/day (IR)
- Insomnia, anxiety, agitation
- Headache
- Dry mouth
- Tremor
- **May worsen anxiety** (not first-line for anxiety disorders)

**Contraindications**:
- Seizure disorder
- Eating disorders (anorexia, bulimia)
- MAOIs (within 14 days)

**Dosing**:
- Start: 150 mg/day (XL)
- Usual: 300 mg/day
- Max: 450 mg/day

**Clinical Pearls**:
- **Drug of choice for patients with sexual dysfunction on SSRIs**
- Good for **smoking cessation**
- **Avoid in anxiety disorders** (may worsen)

### Mirtazapine (Remeron)

**Mechanism**:
- α2-antagonist → ↑NE and 5-HT release
- 5-HT2, 5-HT3 antagonist
- H1 antagonist (sedation, appetite)

**Pharmacokinetics**:
- Oral (tablet, ODT)
- Hepatic metabolism
- Half-life: 20-40 hours

**Clinical Uses**:
1. MDD (especially with insomnia, poor appetite)
2. Insomnia (off-label, low dose)
3. Nausea (5-HT3 antagonism)

**Advantages**:
- **Sedating** → good for insomnia
- **↑Appetite** → good for weight loss, cachexia
- **No sexual dysfunction**
- **No GI side effects** (5-HT3 antagonism)
- Rapid onset (may see effect in 1 week)

**Adverse Effects**:
- **Sedation** (dose-dependent; paradoxically ↓at higher doses >30 mg)
- **Weight gain** (significant)
- ↑Appetite
- Dry mouth
- Constipation
- Dizziness
- Agranulocytosis (rare)

**Dosing**:
- Start: 15 mg qhs
- Usual: 15-45 mg qhs
- **Paradox**: More sedating at 15 mg than 30-45 mg (H1 antagonism predominates at low doses)

**Clinical Pearls**:
- **Good for elderly** (sedating, appetite stimulation)
- **Good for insomnia** (low dose, 7.5-15 mg)
- **Good for underweight patients**
- Often combined with SSRI/SNRI ("California rocket fuel" = venlafaxine + mirtazapine)

### Trazodone (Desyrel)

**Mechanism**:
- 5-HT2A antagonist
- Weak SERT inhibition
- α1 antagonist
- H1 antagonist

**Pharmacokinetics**:
- Oral
- Hepatic metabolism (CYP3A4)
- Half-life: 5-9 hours

**Clinical Uses**:
1. **Insomnia** (most common use - off-label, 25-100 mg qhs)
2. MDD (rarely used at antidepressant doses due to sedation)

**Adverse Effects**:
- **Sedation** (very common - limits antidepressant use)
- Orthostatic hypotension (α1)
- Dizziness
- **Priapism** (rare, <0.01%, but serious - requires emergency treatment)
- Nausea

**Dosing**:
- Insomnia: 25-100 mg qhs
- Depression: 150-600 mg/day (rarely used)

**Clinical Pearl**: **Most commonly used for insomnia**, not depression

### Vilazodone (Viibryd)

**Mechanism**: SSRI + 5-HT1A partial agonist

**Advantages**: May have faster onset, fewer sexual side effects (theoretically)

**Dosing**: 40 mg/day (with food)

### Vortioxetine (Trintellix)

**Mechanism**: SSRI + 5-HT1A agonist + 5-HT3, 5-HT7, 5-HT1D antagonist

**Advantages**:
- May improve cognition
- Lower sexual side effects

**Adverse Effects**: Nausea (common)

**Dosing**: 10-20 mg/day

---

## Clinical Approach to Depression

### First-Line Treatment

**SSRIs or SNRIs**:
- Escitalopram, sertraline (best-tolerated SSRIs)
- Venlafaxine, duloxetine (if comorbid pain)

**Alternatives**:
- Bupropion (if concerned about sexual dysfunction, weight gain)
- Mirtazapine (if insomnia, poor appetite)

### Duration of Treatment

- **First episode**: Continue 6-12 months after remission
- **Second episode**: Continue 2-3 years
- **Three or more episodes**: Consider indefinite treatment

### Inadequate Response (after 4-8 weeks)

1. **Optimize dose** (ensure therapeutic dose)
2. **Switch within class** (e.g., SSRI to different SSRI)
3. **Switch to different class** (e.g., SSRI to SNRI or bupropion)
4. **Augmentation**:
   - Add bupropion (for energy, sexual dysfunction)
   - Add mirtazapine
   - Add aripiprazole (FDA-approved augmentation)
   - Add lithium (augmentation)
   - Add T3 thyroid hormone
5. **Combination therapy** (e.g., venlafaxine + mirtazapine)
6. **Consider TCA or MAOI** (treatment-resistant)

### Treatment-Resistant Depression (TRD)

**Definition**: Failure to respond to ≥2 adequate antidepressant trials

**Options**:
- MAOIs (phenelzine, tranylcypromine)
- Combination therapy
- Augmentation with atypical antipsychotics
- **Electroconvulsive therapy (ECT)** - most effective
- Transcranial magnetic stimulation (TMS)
- Ketamine, esketamine (Spravato)

---

## Clinical Pearls

1. **All antidepressants take 2-4 weeks for effect** - counsel patients
2. **Black Box Warning: Suicidality** in <25 years - monitor closely
3. **SSRIs first-line** for most patients (efficacy, tolerability, safety)
4. **Bupropion for sexual dysfunction/weight concerns** - no serotonergic activity
5. **Mirtazapine for insomnia/appetite** - sedating, weight gain
6. **Duloxetine for comorbid pain** - FDA-approved for neuropathic pain, fibromyalgia
7. **Paroxetine worst discontinuation syndrome** - taper slowly
8. **Fluoxetine no discontinuation syndrome** - long half-life
9. **TCAs lethal in overdose** - avoid in suicidal patients
10. **MAOIs require dietary restrictions** - reserved for treatment-resistant
11. **Serotonin syndrome with drug combinations** - recognize triad
12. **Taper when discontinuing** - prevent withdrawal
13. **Monitor sodium in elderly** - SSRI-induced SIADH
14. **Bleeding risk with NSAIDs + SSRIs** - counsel patients

---

## Key Takeaways

1. **SSRIs**: First-line, block SERT, well-tolerated, sexual dysfunction common
2. **SNRIs**: Dual mechanism (SERT + NET), helpful for pain
3. **TCAs**: Effective but toxic (anticholinergic, cardiac, lethal overdose)
4. **MAOIs**: Reserved for treatment-resistant, tyramine reaction risk
5. **Bupropion**: NDRI, no sexual dysfunction, no weight gain, seizure risk
6. **Mirtazapine**: α2-antagonist, sedating, weight gain, good for insomnia
7. **Trazodone**: Primarily used for insomnia (low dose), priapism risk
8. **Serotonin syndrome**: Mental status changes, autonomic hyperactivity, clonus
9. **Discontinuation syndrome**: FINISH symptoms, taper to prevent
10. **Time to effect**: 2-4 weeks minimum, counsel patients
11. **Black Box Warning**: Suicidality in youth - monitor closely
12. **Treatment-resistant**: Consider MAOIs, ECT, augmentation strategies

---

## References

1. Stahl's Essential Psychopharmacology, 5th Edition
2. Katzung's Basic & Clinical Pharmacology, 15th Edition
3. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
4. American Psychiatric Association Practice Guidelines for Major Depressive Disorder
5. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005.
6. FDA Drug Safety Communications - Antidepressants
